Cadrenal Therapeutics, Inc. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cadrenal Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-09-30 was $98.93K, a 79.33% decline year-over-year.
- Cadrenal Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-06-30 was $113.66K.
- Cadrenal Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2023-03-31 was $286.40K.
- Cadrenal Therapeutics, Inc. stock issued during period, value, restricted stock award, gross for the quarter ending 2022-09-30 was $478.68K.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2023-09-30 | $98.93K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $113.66K 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $286.40K 10-Q · filed 2024-05-09 | |
| 2022-09-30 | $478.68K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |